Anika Therapeutics, Inc. (ANIK)

Stock NASDAQ

$12.92

-0.41 (-2.97%)

Delayed quote.

Price history

Daily close
ANIK daily closing price, Nov 17, 2025 to Nov 16, 2026 Closed at $9.65 on Nov 17, 2025 and $12.92 on Nov 16, 2026, a change of +33.89%. Range $9.13 to $22.03.
Daily closes, Nov 17, 2025 to Nov 16, 2026 (251 trading days).
Start
$9.65
Latest close
$12.92
Period change
+33.89%
Period low
$9.13
Period high
$22.03

Key metrics

Market cap
$179.50M
Volume
87.8K
Average volume
104.6K
52-week range
$7.87 – $22.88
Beta
0.21
Last dividend
—
EPS (TTM)
-$0.13
P/E ratio
-12.64
Revenue (TTM)
$123.43M
Net income (TTM)
-$1.77M
Total assets
$189.60M
Total debt
$24.57M
Cash and equivalents
$44.96M

Key financials (trailing twelve months).

Company profile

Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.

Sector
Healthcare
Industry
Medical - Specialties
Exchange
NASDAQ
CEO
Stephen D. Griffin
Employees
235
Headquarters
Bedford, MA, US
IPO date
1993-05-03

Financial statements

Annual, last 3 fiscal years. Most recent period first. Reported in USD.

Income statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Revenue$112.82M$119.91M$120.79M
Gross profit$63.81M$76.00M$82.53M
Operating income-$11.05M-$5.10M$844.0K
EBITDA-$3.58M$5.36M$17.37M
Net income-$10.88M-$56.38M-$82.67M
Diluted EPS-$0.76-$3.83-$5.64
Balance sheet
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Cash and equivalents$57.48M$55.63M$68.74M
Total assets$190.27M$202.74M$270.63M
Total liabilities$46.80M$48.75M$58.37M
Total debt$26.25M$25.93M$27.74M
Shareholders’ equity$143.47M$153.99M$212.26M
Cash flow statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Operating cash flow$11.19M$5.40M-$1.79M
Capital expenditure-$6.83M-$7.73M-$5.43M
Free cash flow$4.36M-$2.33M-$7.21M

Quarterly, last 6 quarters. Most recent period first. Reported in USD.

Income statement
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Revenue$30.59M$32.61M$29.61M$30.61M$27.82M$28.22M
Gross profit$18.84M$21.24M$19.00M$19.18M$15.58M$14.36M
Operating income-$712.0K$2.95M-$5.49M$646.0K-$3.23M-$4.18M
EBITDA$1.58M$4.88M-$3.41M$2.08M-$833.0K-$2.55M
Net income-$311.0K$3.31M-$5.06M$292.0K-$2.33M-$3.97M
Diluted EPS-$0.02$0.24-$0.37$0.02-$0.16-$0.28
Balance sheet
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Cash and equivalents$44.96M$38.41M$41.02M$57.48M$57.99M$53.17M
Total assets$189.60M$183.47M$179.39M$190.27M$189.44M$187.68M
Total liabilities$52.02M$46.19M$45.49M$46.80M$42.63M$40.01M
Total debt$24.57M$23.32M$25.74M$26.25M$24.51M$24.99M
Shareholders’ equity$137.58M$137.28M$133.90M$143.47M$146.81M$147.67M
Cash flow statement
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Operating cash flow$8.38M-$684.0K-$4.85M$4.64M$6.87M-$189.0K
Capital expenditure-$1.66M-$1.45M-$1.43M-$648.0K-$1.89M-$1.47M
Free cash flow$6.72M-$2.13M-$6.28M$3.99M$4.98M-$1.66M